Seeking Alpha

Midday top 10 gainers / Losers

Comments (1)
  • Scrying Biotech
    , contributor
    Comments (1693) | Send Message
    'I'm now going to give investors a look ahead at that Omecamtiv Phase III readout. It won't be good! Try though they may to make the numbers look their best the truth will surface. Omecamtiv won't work as a therapy over the extended duration of time this trial requires.'


    From an article dated June 13, 2013 found here:


    Scrying Biotech: Foretell the Future
    3 Sep 2013, 02:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector